An observational study in Breast Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center. Completed at 1 site in United States. Open to female participants aged 35 Years to 64 Years. Per ClinicalTrials.gov, last updated 2022-11-09.
Sponsored by Ohio State University Comprehensive Cancer Center · Observational
This study develops a genetic counseling patient preference intervention for women at elevated risk for breast cancer. This study aims to develop an intervention that may deliver educational videos about breast cancer, heredity, multigene tests results and polygenic risk score, provide multigene and polygenic test results, obtain information about patients' questions/ concerns about test results to use in post-genetic test counseling, and determine patient preference (e.g. telephone) for receipt of post-genetic test counseling.
PRIMARY OBJECTIVE:
I. Develop the Genetic Counseling Patient Preference (GCPP) intervention in collaboration with community members.
OUTLINE:
Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 8 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Ohio State University Comprehensive Cancer Center is the lead sponsor of 369 studies on the registry; 81 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women at elevated risk for breast cancer
Inclusion Criteria:
Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
Procedure: Discussion
Attend a focus group
Also known as: Discuss
Development of Genetic Counseling Patient Preference (GCPP) intervention
Time frame: Up to 2 years
Plan to share: No
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ohio State University Comprehensive Cancer Center